藥物成份

共有 21645 個藥物成份

Imipenem and Cilastatin for injection is a sterile mixture of Imipenem, Cilastatin Sodium, and Sodium Bicarbonate. It contains not less than 90.0 percent and not more than 115.0 percent of the labeled amounts of Imipenem(C12H17N3O4S) and Cilastatin (C16H26N2O5S)

• 關聯藥證數量: 1

Imipenem and Cilastatin sodium for Injection is a sterile mixture of Imipenem, Cilastatin Sodium, and Sodium Bicarbonate. It contains not less than 90.0 percent and not more than 115.0 percent of the labeled amounts of imipenem (C12H17N3O4S) and cilastatin (C16H26N2O5S).

• 關聯藥證數量: 1

Imipenem contains the equivalent of not less than 98.0 percent and not more than 101.0 percent of imipenem monohydrate (C12H17N3O4S？H2O)

• 關聯藥證數量: 1

Imipenem, Meropenem

• 關聯藥證數量: 1

Imipramine Hydrochloride contains 98.5% to 101.0% (dried substance).

• 關聯藥證數量: 1

Imipramine Hydrochloride contains not less than 98.5% and not more than 101.0% of C19H25ClN2, calculated on the dried substance.

• 關聯藥證數量: 1

Immidazole 100 mmol/l ;NADP 2.0 mool/l\nADP 2.0mmol/l ;AMP 5.0 mmol/l\nEDTA 2.0 mool/l ;Glucose 20 mmol/l\nCreatine phosphate 30 mmol/l ;N-acetylcysteine 0.2 mmol/l\nActivator 26 mmol/l ;Mg2+ 10 mmol/l\nDiadenosine pentaphosphate 0.01 mmol/l ;HK≧4.0 kU/l\nG6P-DH≧2.8 kU/ ;Stabilisers;Preservative\n

• 關聯藥證數量: 1

Immucor 22% Bovine Albumin reagents are prepared from bovine serum albumin. Each solution is to be used as supplied.

• 關聯藥證數量: 1

Immucor Anti-K blood grouping reagent is prepared from pools of human sera containing the appropriate antibody.Each pool is diluted in a sodium chloride solution to which bovine albumin has been added. Sodium azide (0.1%) has been added as a preservative to the reagent.

• 關聯藥證數量: 1

Immucor Anti-M Blood Grouping Reagent is prepared from pools of human serum diluted in a saline chloride solution to which bovine albumin is added. Sodium azide (0.1%) has been added as a preservative to this reagent.

• 關聯藥證數量: 1

ImmunoCAP Allergen c1, Penicilloyl G：Penicilloyl G\nImmunoCAP Allergen c2, Penicilloyl V：Penicilloyl V \nImmunoCAP Allergen c73, Insulin human：Insulin human\nImmunoCAP Allergen c70, Insulin porcine：Insulin procine\nImmunoCAP Allergen c71, Insulin bovine： Insulin bovine\nImmunoCAP Allergen c5, Ampicilloyl： Ampicilloyl\nImmunoCAP Allergen c6, Amoxicilloyl：Amoxicilloyl\nImmunoCAP Allergen c74, Gelatin bovine：Gelatin bovine \nImmunoCAP Allergen c202, Suxamethonium (succinylcholine)：Suxamethonium (succinylcholine) \nImmunoCAP Allergen c7, Cefaclor：Cefaclor

• 關聯藥證數量: 1

ImmunoCAP Allergen h1, Greer Labs. Inc.：\nGreer Labs. Inc. \nImmunoCAP Allergen h2, Hollister-Stier Labs.：Hollister-Stier Labs. \nImmunoCAP Allergen hx2, House dust：\nHollister-Stier Labs. Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blatella germanica\n

• 關聯藥證數量: 1

ImmunoCAP Allergen o70, Seminal fluid : Seminal fluid ; ImmunoCAP Allergen o1, Cotton, crude fibers : Cotton, crude fibers ; ImmunoCAP Allergen o201, Tobacco leaf : Tobacco leaf

• 關聯藥證數量: 1

ImmunoCAP Rapid Inhalant Profile 1 contains: 10 allergens and gold-anti-IgE Conjugate (mouse monoclonal).\nImmunoCAP Rapid Developer Solution contains: Phosphate buffer, Surfactant Sodium Azide <0.1%.\nImmunoCAP Rapid Positive QC 1 contains: Human plasma, Sodium azide 0.05%.\nImmunoCAP Rapid Negative Control 1 contains: Human plasma, Sodium azide 0.05%.\n

• 關聯藥證數量: 1

ImmunoCAP Specific IgE Calibrator Strip 0-100: (human IgE in buffer) Conc.: 0; 0.35; 0.7; 3.5; 17.5 and 100 kU/l, Kathon CG 0.15%

• 關聯藥證數量: 1

ImmunoCAP Specific IgE Calibrators 0-100: (human IgE in buffer)

• 關聯藥證數量: 1

Imx PAP MODE 1 Calibrator\n3 Bottles (4mL each) MODE 1 Calibrator (C).

• 關聯藥證數量: 1

Inactivated EV71 whole virus

• 關聯藥證數量: 1

Inclisiran Sodium

• 關聯藥證數量: 1

Incubation lids、ID 32 E strips:\nL-ornithine, L-arginine, L-lysine, urea, L-arabitol, galacturonic acid, potassium 5-ketogluconate, 5-bromo-3-indoxyl-nonanoate, sodium pyruvate, 4-nitrophenyl-βD-glucopyranoside, D-mannitol, D-maltose, adonitol, palatinose, 4-nitrophenyl-βD-glucuronide,

• 關聯藥證數量: 1

Indapamide contains not less than 98.0 per cent and not more than the equivalent of 102.0 per cent of C16H16ClN3O3S calculated with reference to the anhydrous substance.

• 關聯藥證數量: 1

Indapamide contains not less than 98.0% and not more than 102.0% of C16H16CIN3O3S,calcuated with reference to the anhydrous substance.

• 關聯藥證數量: 1

Indapamide contains not less than 98.0% and not more than 102.0% of C16H16ClN3O3S, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Indapamide content not less than 98.0% and not more than 102.0% of C16H16CIN3O3S, calculated on anhydrous substance.

• 關聯藥證數量: 1

Indicator Cells (1x5 mL): An approximate 0.5% suspension of ficin-treated group O red blood cells obtained from a donor of the DcE(R2R2) phenotype.\nPositive Control (1x2 mL): A 2-4% suspension of red blood cells comprising approximately 99.4% of group O D-negative cells and approximately 0.6% group O D-positive cells obtained from a donor having heterozygous expression of the D antigen.

• 關聯藥證數量: 1

Individually Packaged Test Strips (25): Mouse monoclonal anti-influenza A and anti-influenza B antibodies\nExtraction Tubes (25): Lyophilized buffer detergents and reducing agents \nDisposable Droppers (25)\nSterile Swabs (25)\nPositive Influenza Type A Control Swab (1): Swab is coated with non-infectious recombinant influenza A antigen\nPositive Influenza Type B Control Swab (1): Swab is coated with non-infectious recombinant influenza B antigen\nNegative Control Swab (1): Swab is coated with formalin-inactivated, non-infectious Streptococcus C antigen\n

• 關聯藥證數量: 1

Indometacin contains not less than 98.5% and not more than the equivalent of 100.5% of [1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid, calculated with reference to the dried substance.

• 關聯藥證數量: 1

Indomethacin (Indometacin) contains not less than 98.5% and not more than the equivalent 100.5% of [1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid, calculated with reference to the dried substance.

• 關聯藥證數量: 1

Indomethacin (Indometacin) contains not less than 98.5% and not more than the equivalent of 100.5% of [1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl] acetic acid, calculated with reference to the dried substance.

• 關聯藥證數量: 1

Indomethacin contains not less than 98.5% and not more than the equivalent of 100.5% of [1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid, calculated with reference to the dried substance.

• 關聯藥證數量: 1

Inebilizumab

• 關聯藥證數量: 1

Influenza A virus: 1. Antigen 2.Control antigen 3. Postive Control 4. Negative Control

• 關聯藥證數量: 1

Influenza Virus A/H1N1 Strain, Split Virion, Inactivated

• 關聯藥證數量: 1

Influenza Virus A/H3N2 Strain, Split Virion, Inactivated

• 關聯藥證數量: 1

Influenza Virus B Strain, Split Virion, Inactivated

• 關聯藥證數量: 1

Ingredient Quantity\nCholesterol 2.222g/L\nSurfactant certain

• 關聯藥證數量: 1

Ingredient Quantity\nTransferrin (human) 3g/L,\nBovine Serum Albumin certain, \n1M Hydrochloric acid certrain.

• 關聯藥證數量: 1

Ingredient \nPiperacillin Sodium\n(863~1007ug/mg, calculated on the anhydrous basis)\n\n依據USP 34

• 關聯藥證數量: 1

Ingredient: \nLithium Dye Reagent\nLithium Alkaline Salt Reatent\nLithium Blank Reagent

• 關聯藥證數量: 1

Ingredients Amount(g) %by\nweight Purpose in formulation\nPart B-Outer cup \nMonosodium Phosphare，CAS#7558-80-7 19.68 12.02 Buffer\nPegol L-61 (Ethoxylated Polyoxypropylene) CAS#9003-11-6 0.51 0.31 Detergent\nlgepal Co-720 (Nonylphenoxypoly (ethyleneoxy)-ethanol，CAS#9016-45-9 0.51 0.31 Detergent\nCobratec 99 powder (Benzotrazole)CAS#95-14-7 7.68 4.69 Anti-corrosive\nDisodium Phospahte, Anhydrous CAS#7558-79-4 98.09 59.92 Buffer\nSodium Hexmetaphosphate，CAS#68915-3-1 2.44 1.49 Sequestering Agent\nSodium Moybdate, Crystalline，CAS#7631-95-0 9.49 5.80 Anti-corrosive\nTetrasodium ethylenediamine \nTetraaacetate, tetrahydrate(EDTA)\nCAS#64-02-8 9.49 5.80 Chelant\nTrisodium nitriloaceate monohydrate\nCAS#18662-53-8 4.76 2.91 Chelant\nSodium polyacrylate，CAS#9003-04-7 4.76 2.91 Chelant\nSodium hydroxide，CAS#1310-73-2 2.59 1.58 Base\nWater 3.70 2.26 Additive\n Total Weight\n163.70g 100% \nPart A-Inner cup \nPeracetic Acid, 35%，CAS#79-21-0 67.5 100 Sterilant\n*Peracetic acid of Peracetic acid 35% N/A 35 Sterilant\n

• 關聯藥證數量: 1

Ingredients and concentration related to reaction Enzyme sol(R-1)：Good's buffer pH 7.0 (37℃) α-Glucosidase 8000 U/L Substrate sol.(R-2)：Good's buffer pH 7.0 (37℃) Et-G7pNP 1.0 mmol/L α-Glucosidase ：(EC3.2.1.20)bacteria 6.3x10-4(G2-G4) Et-G7pNP ：Ethylidene-p-nitrophenyl-alpha-D-maltoheptaoxide

• 關聯藥證數量: 1

Ingredients and concentration related to reactionsCoenzyme sol (R-1): NADP+ 2.3 mmol/L ATP 2.3 mmol/L Tris buffer pH 7.4 (25°C)Enzyme sol (R-2): HK 3000 U/L G-6-PD 1500U/L Tris buffer pH 7.4 (25°C)*1:HK: (EC2.7.1.1) bacteria 2.3×10-4 (Glu.) 1.9×10-4 (ATP)*2:G-6-PD: (EC 1.1.1.49) bacteria 3.7×10-5 (NADP+) 2.0×10-4 (G-6-P)

• 關聯藥證數量: 1

Ingredients and concentration related to reactionsColor reaction sol (R-1): BCG 0.20 mmol/L Citrate buffer (containing a surfactand), pH 3.9 (25°C)

• 關聯藥證數量: 1

Ingredients of slide(Bromocresol green) 0.125mg

• 關聯藥證數量: 1

Ingredients\nBuffer：Citrate buffer (pH 2.9) 0.1 mol/L\n Detergent\nVanadate：Phosphate buffer (pH 7.0) 10 mmol/L\n Sodium metavandadate 4 mmol/L

• 關聯藥證數量: 1

Ingredients：Quatemary Ammonium Salt <1.0%\n Potassium Cyanide <0.01%

• 關聯藥證數量: 1

Ingredient：Rosuvastatin Calcium Content：97.0~102.0% anhydrous substance

• 關聯藥證數量: 1

Inhibitor, Biotinylated, StreptAvidin HRP, DAB, DAB H202, Copper。

• 關聯藥證數量: 1

Innovance D-Dimer Control 1 and Innovance D-Dimer Control 2 are lyophilized human plasma based products contianing D-Dimer.

• 關聯藥證數量: 1

Innovance D-Dimer buffer：liquid; buffered saline solution with deteregent and polymeric carbohydrates.

• 關聯藥證數量: 1

Innovance D-Dimer calibrator：lyophilized human plasma based product containing D-Dimer preparation (4.4 to 6.1 mg/L FEU)

• 關聯藥證數量: 1

Innovance D-Dimer diluent：liquid; buffered saline solution with detergent

• 關聯藥證數量: 1

Innovance D-Dimer reagent：lyophilized; contains polystyrene particles coated with monoclonal mouse antibodies(0.1 gL antibodies Produced in accordance with an arrangement with INNOGENETICS N.V.) in a buffered matrix, containing human Serum albumin.

• 關聯藥證數量: 1

Innovance D-Dimer supplement：liquid; buffered saline solution with proteins (Heterophilic Blocking Reagent; HBR)

• 關聯藥證數量: 1

Inositol, contains not less than 97.0% of C6H12O6

• 關聯藥證數量: 1

Inotuzumab Ozogamicin

• 關聯藥證數量: 1

Insstruction Leaflet: giving full assay details.\nQC Certificate: indicating the expected performance of the batch\nβ2GP1 Coated Wells: 12breakpart 8 well strips coated with human β2GP1 antigen.\nType II Sample Diluent: 2 bottles containing 50 ml of buffer for sample dilution.\nWash Buffer (20x Concentrate): 1 bottle containing 50 ml of a 20-fold concentrated buffer for washing the wells.\nβ2GP1 IgM Calibrators: 5 bottles each containing 1.2 ml of diluted human serum, with the following concentrations of anti-β2GP1 autoantibody: 300, 100, 33.3, 11.1, 3.7 U/ml.\nβ2GP1 IgM Positive Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is given on the QC certificate.\nβ2GP1 Negative Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is given on the QC certificate.\nβ2GP1 IgM Conjugate: 1 bottle containing 12 ml of purified peroxidase labeled antibody.\nTMB Substrate: 1 bottle containing 14 ml TMB substrate.\nStop Solution: 1 bottle containing 14 ml of 3M phosp

• 關聯藥證數量: 1

Instruction Leaflet: Giving full assay details.\nQC Certificate: Indicating the expected performance of the batch.\nCardiolipin Coated Wells: 12 breakapart 8 well strips coated with bovine cardiolipin antigen.\nType II Sample Diluent: 2 bottles containing 50 ml of buffer for sample dilution.\nType II Wash Buffer (20x concentrate): 1 bottle containing 50 ml of a 20-fold concentrated buffer for washing the wells.\nCardiolipin IgG Calibrators: 5 bottles each containing 1.2 ml of diluted human serum, with the following concentrations of anticardiolipin autoantibody: 100, 50, 25, 12.5, 6.25 MPL U/ml.\nCardiolipin IgG Positive Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is given on the QC certificate.\nCardiolipin Negative Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is given on the QC certificate.\nCardiolipin IgG Conjugate: 1 bottle containing 12 ml of purified peroxidase labeled antibody.\nTMB Substrate: 1 bottle containing 14 ml TMB substrate.

• 關聯藥證數量: 1

Instruction Leaflet: Giving full assay details.\nQC Certificate: Indicating the expected performance of the batch.\nCardiolipin Coated Wells: 12 breakapart 8 well strips coated with bovine cardiolipin antigen.\nType II Sample Diluent: 2 bottles containing 50 ml of buffer for sample dilution.\nType II Wash Buffer (20x concentrate): 1 bottle containing 50 ml of a 20-fold concentrated buffer for washing the wells.\nCardiolipin IgM Calibrators: 5 bottles each containing 1.2 ml of diluted human serum, with the following concentrations of anticardiolipin autoantibody: 100, 50, 25, 12.5, 6.25 MPL U/ml.\nCardiolipin IgM Positive Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is given on the QC certificate.\nCardiolipin Negative Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is given on the QC certificate.\nCardiolipin IgM Conjugate: 1 bottle containing 12 ml of purified peroxidase labeled antibody.\nTMB Substrate: 1 bottle containing 14 ml TMB substrate.

• 關聯藥證數量: 1

Instruction Leaflet: Giving full assay details.\nQC Certificate: Indicating the expected performance of the batch.\ndsDNA Coated Wells: 12 breakapart 8 well strips coated with calf thymus dsDNA antigen. Each plate is packaged in a resealable foil bag containing two desiccant pouches.\nType III Sample Diluent: 2 bottles containing 50 ml of buffer for sample diluent.\nType III Wash Buffer (20x Concentrate): 1 bottle containing 50 ml of a 20-fold concentrated buffer for washing the wells.\ndsDNA Calibrators: 5 bottles each containing 1.2 ml of diluted human serum, with the following concentrations of anti-dsDNA autoantibody: 1000, 333, 111, 37, 12.3 IU/ml.\ndsDNA Positive Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is given on the QC certificate.\ndsDNA Negative Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is given on the QC certificate.\ndsDNA Single Strandard Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is gi

• 關聯藥證數量: 1

Instruction Leaflet: giving full assay details.\nQC Certificate: indicating the expected performance of the batch.\nCardiolipin Coated Wells: 12 breakapart 8 well strips coated with bovine cardiolipin antigen. \nType II Sample Diluent: 2 bottles containing 50 ml of buffer for sample dilution.\nType II Wash Buffer (20x Concentrate): 1 bottle containing 50 ml of a 20-fold concentrated buffer for washing the wells.\nCardiolipin IgA Calibrators: 5 bottles each containing 1.2 ml of diluted human serum, with the following concentrations of anticardiolipin autoantibody: 100, 50, 25, 12.5, 6.25 MPL U/ml.\nCardiolipin IgA Positive Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is given on the QC certificate.\nCardiolipin IgA Negative Control: 1 bottle containing 1.2 ml of diluted human serum. The expected value is given on the QC certificate.\nCardiolipin IgA Conjugate: 1 bottle containing 12 ml of purified peroxidase labeled antibody.\nTMB Substrate: 1 bottle containing 14 ml TMB subst

• 關聯藥證數量: 1

Instruction Leaflet: giving full assay details.\nQC Certificate: indicating the expected performance of the batch.\nENA Coated Wells: 12 x 8 well strips coated with a mixture of purified antigens (SSA/Ro (60 and 52 kD), SSB/La, Sm, Sm/RNP, Scl-70 and Jo-1).\nType III Wash Buffer 20x concentrate: 1 bottle containing 50 ml of a 20x concentrated buffer for washing the wells.\nType III Sample Diluent: 2 bottles containing 50 ml of buffer for diluting the samples.\nENA Screen Cut-off Control: 1 bottle containing 1.9 ml of diluted stabilized human serum. The expected ENA result is given on the QC certificate.\nENA Screen Positive Control: 1 bottle containing 1.9 ml of diluted stabilized human serum. The expected ENA result is given on the QC certificate.\nENA Negative Control: 1 bottle containing 1.9 ml of diluted stabilized human serum. The expected ENA result is given on the QC certificate.\nENA Screen Conjugate: 1 bottle containing 12 ml of peroxidase labeled antibody to human IgG.\nTMB Substrate: 1 bottle conta

• 關聯藥證數量: 1

Instrument, equipment and supplies: BDProbeTec ET Instrument and Instrument Plates, BDProbeTec ET Lysing Heater, Lysing Rack and base, BDProbeTec ET Priming and Warming Heater, BDProbeTec ET Pipettor and Power Supply, BDProbeTec ET Urine Processing Kit (containing Urine Processing Pouches/UPPs), BDProbeTec ET Sample Tubes, Caps, and Pipette Tips, BDProbeTec ET Chlamydia trachomatis/Neisseria gonorrhoeae (CT/GC) Amplified DNA Assay Endocervical Specimen Collection and DRY TRANSPORT Kit or BDProbeTec ET Chlamydia trachomatis/Nesseria gonorrhoeae (CT/GC) Amplified DNA Assay Collection Kit for Endocervical Specimens, BDProbeTec ET Chlamydia trachomatis/Neisseria gonorrhoeae (CT/GC) Amplified DNA Assay Male Urethral Specimen Collection and DRY TRANSPORT Kit or BDProbeTec ET Chlamydia trachomatis/Neisseria gonorrhoeae (CT/GC) Amplified DNA Assay Collection Kit for Male urethral Specimens.

• 關聯藥證數量: 1

Instrument: 2.5 x 4.5 x 9.0 inches\nCuvette: pre-loaded with dried thromboplastin with added stabilizers and buffers.

• 關聯藥證數量: 1

Insulin Bead Pack (L2IN12) : beads, coated with monoclonal murine anti-insulin antibody. \nInsulin Reagent Wedge (L2INA2) : alkaline phosphatase (bovine calf intestine) conjugated to polyclonal sheep anti-insulin antibody and alkaline phosphatase (bovine calf intestine) conjugated to monoclonal murine anti-insulin antibody in buffer.\nInsulin Adjustors (LINL, LINH) : Low and High Iyophilized insulin in a nonhuman serum matrix \nInsulin Controls (LINC1, LINC2) : lyophilized insulin in a nonhuman serum matrix

• 關聯藥證數量: 1

Insulin Test Units:\ncoated with monoclonal murine anti-insulin. \nInsulin Reagent Wedge:\nalkaline phosphatase (bovine calf intestine)conjugated to polyclonal sheep anti-insulin antibody and alkaline phosphatase (bovine calf intestine) conjugated to monoclonal murine anti-insulin antibody in buffer. \nInsulin Adjustors:\nTwo vials (Low and High) of lyophilized insulin in a nonhuman serum matrix. \nInsulin Controls:\nTwo vials of lyophilized insulin in a nonhuman serum matrix. \nInsulin Sample Diluent:\ninsulin-free nonhuman serum matrix.

• 關聯藥證數量: 1

Intact PHT Reagent: 200 beads, coated with affinity-purified murine monoclonal anti-PTH (44-84) antibody. 11.5 mL alkaline phosphatase (bovine calf intestine) conjugated to affinity-purified goat polyclonal anti-PTH (1-34) in buffer. Two vials (Low and High) of lyophilized, synthetic human intact PTH in a buffered matrix.\nIntact PTH Sample Diluent: 25 mL of concentrated PTH-free buffer matrix.

• 關聯藥證數量: 1

Intact PTH Adjustors : Two vials (Low and High) of lyophilized synthetic human intact PTH in a buffered matrix.

• 關聯藥證數量: 1

Intact PTH Test Units: one bead coated with affinity-purified murine monoclonal anti-PTH (44-84) antibody. Intact PTH Reagent Wedge: alkaline phosphatase (bovine calf intestine); conjugated to affinity-purified goat polyclonal anti-PTH (1-34) antibody in buffer, with preservative. Intact PTH Adjustors: synthetic human intact PTH in a buffered matrix.Sample Diluent: PTH-free buffer matrix, with preservative.

• 關聯藥證數量: 1

Ion Correct S is a liquid serum prepared from strictly selected normal human sera.

• 關聯藥證數量: 1

Ipecac Fluidextract

• 關聯藥證數量: 1

Ipecacuanha Liquid Extract contains not less than 1.8% and not more than 2.2% of total alkaloids, expressed as emetine (C29H40N2O4).

• 關聯藥證數量: 1

Ipilimumab

• 關聯藥證數量: 1

Ipratropium Bromide contains not less than 99.0% and not more than 100.5% of C20H30BrNO3‧H2O, calculated on the anhydrous substances.

• 關聯藥證數量: 1

Ipratropium Bromide contains not less than 99.0% and not more than 100.5% of C20H30BrNO3‧H2O, calculated on the dried basis.

• 關聯藥證數量: 1

Ipratropoium Bromide contains not less than 99.0% and not more than 100.5% of Ipratropoium bromide (C20H30BrNO3‧H2O), calculated on the anhydrous basis.

• 關聯藥證數量: 1

Irbesartan contains not less than 98.0 percent and not more than 102.0 percent of C25H28N6O, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Irbesartan contains not less than 98.0% and not more than 102.0% of C25H28N6O, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Irbesartan contains not less than 98.0% and not more than 102.0% of C25H28N6O, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Irbesartan contains not less than 98.0% and not more than 102.0% of C25H28N6O, calculated on the dried basis.

• 關聯藥證數量: 1

Irbesartan contains not less than 99.0% and not more than 101.0% of C25H28N6O, calculated on anhydrous substance.

• 關聯藥證數量: 1

Irinotecan Hydrochloride Trihydrate contains not less than 98.0% and not more than 102.0% of C33H38N4O6‧HCl, calculated on anhydrous substance.

• 關聯藥證數量: 1

Irinotecan Hydrochloride contains not less than 98.0% and not more 102.0% of Irinotecan Hydrochloride (C33H38N4O6˙HCl), calculated on the anhydrous basis.

• 關聯藥證數量: 1

Irinotecan Hydrochloride contains not less than 98.0% and not more than 102.0% of C33H38N4O6‧HCl, calculated on anhydrous substance.

• 關聯藥證數量: 1

Irinotecan Hydrochloride contains not less than 98.0% and not more than 102.0% of C33H38N4O6。HCl, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Irinotecan hydrochloride contains not less than 98.0 percent and not more than 102.0 percent of C33H38N4O6HCl？3H2O calculated on the dried basis.

• 關聯藥證數量: 1

Iron (III) Hydroxide Polymaltose Complex [(Fe(OH)3(H2O)15)]n．[(C6H10O5)m]x Assay Polymaltose content (on Anhydrous basis): between 25.0 and 50.0%. ww Iron content (on as basis): between 25.0 and 40.0% ww

• 關聯藥證數量: 1

Iron (as Ferrous Fumarate)

• 關聯藥證數量: 1

Iron Color Reagent:\nFerrozine 7.8 mmol/L\nNeocuproine 14.4 mmol/L\nHydroxylamine Hydochloride 220 mmol/L\nIron HA Buffer:\nHydroxylamine Hydochloride 220 mmol/L、Surfactants\nIron TRIS Buffer:\nTRIS 500 mmol/L、Surfactants\n\n

• 關聯藥證數量: 1

Iron Solution 1 x 100 mL\nBasic Magnesium Carbonate 2 x 10 g

• 關聯藥證數量: 1

Iron Standard 500 μg/dl.\nReactive Ingredient: 0.09 mmol/l Ferrous ammonium sulfate. \nNonreactive Ingredient: Dilute Sulfuric acid.

• 關聯藥證數量: 1

Iron Sucrose Complex Solution ([Na2Fe5O8(oH)3H2O]n‧m(C12H22O11)]) Assay for Iron (by UV) Not less than 3.4% w/w. Assay for sucrose by HPLC (2.0% W/V of Iron solution) Not less than 260 mg and not more than 340 mg of sucrose per ml.

• 關聯藥證數量: 1

Iron Sucrose contains not less than 50.00 percent and not more than 65.00 percent of Sucrose and not less than 3.50 percent and not more than 4.00 percent of Iron on dried basis.

• 關聯藥證數量: 1

Iron Sucrose contains not less than 80.00 percent and not more than 90.00 percent of Sucrose and not less than 5.00 percent and not more than 6.00 percent of Iron on dried basis.

• 關聯藥證數量: 1

Iron Sucrose is an aqueous sloution of ferric hydroxide in complex with sucrose. It contains not less than 3.5% and not more than 4.0% of iron,and not less than 45.0% and not more than 65.0% of sucrose(C12H22O11).The ratio of sucrose and iron is between 13.0-17.0.

• 關聯藥證數量: 1

Isavuconazonium sulfate

• 關聯藥證數量: 1

Isoleucine (L-Isoleucine), when dried, contains not less than 98.5% and not more than 101.0% of L-Isoleucine (C6H13NO2).

• 關聯藥證數量: 1

Isoleucine contains not less than 98.5% and not more than 101.5% of C6H13NO2, as L-Isoleucine, calculated on the dried basis.

• 關聯藥證數量: 1

Isoniazid contains not less than 98.0% and not more than 102.0% of C6H7N3O, calculated on the dried substance.

• 關聯藥證數量: 1

Isoniazid contains not less than 99.0% and not more than the equivalent of 101.0% of C6H7N3O calculated with reference to the dried substance.

• 關聯藥證數量: 1